Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


Real-time Estimate Quote. Real-time Estimate CHI-X - 10/27 11:55:00 am
431.95 DKK   -1.59%
10:15aNOVO NORDISK A/S : quaterly earnings release
10/26NOVO NORDISK A/S : – Share repurchase programme
10/16NOVO NORDISK : Buy rating from Goldman Sachs
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : launches new 100% renewable power target for suppliers

share with twitter share with LinkedIn share with facebook
09/21/2020 | 11:24am EDT

Bagsvaerd - Novo Nordisk today announced an ambitious target to ensure all its direct suppliers supply the company based on 100% renewable power by 2030.

Novo Nordisk will work with all existing and new suppliers to meet the target. The plan will be presented in connection with Climate Week NYC hosted this week in association with the United Nations and the City of New York.

This commitment is the next step in Novo Nordisk's 'Circular for Zero' environmental strategy, which launched in April 2019 and set an ultimate ambition for the company to have zero environmental impact.

The majority of Novo Nordisk's total carbon emissions originate in its supply chain, making this commitment with suppliers on renewable power integral to achieving Novo Nordisk's environmental strategy. In achieving this target, Novo Nordisk would therefore be eliminating at least 300,000 tons of greenhouse gases from its supply chain. Novo Nordisk has already committed to achieve zero CO2 emissions from the company's own global operations and transport by 2030 and, in 2020, achieved the target of using 100% renewable power across its global production.

'Our ambition of achieving zero environmental impact is a cornerstone of our aspiration to be a truly sustainable business,' said CEO Lars Fruergaard Jorgensen. 'Achieving it requires that we look beyond our own organisation and collaborate across multiple sectors with suppliers to accelerate the transition to renewable power. We hope that others across the corporate sector will also benefit from these actions. I would like to pay tribute to the commitment of our suppliers, on whom this new ambition depends.'

To reach the target, Novo Nordisk will work alongside suppliers, sharing with them what it has learned on embedding renewable power through its operations. Suppliers' ability to meet the 100% renewable power target will be continually evaluated.

SCHOTT, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk, has committed to becoming carbon neutral by 2030. Sourcing renewable power will be one pillar of their company strategy. SCHOTT CEO Dr Frank Heinricht said: 'Our transition to carbon neutrality is fuelled by close exchange and collaboration with valued customers. As one example, Novo Nordisk has shared valuable insights from their own experiences of sourcing renewable power. As part of our Zero Carbon strategy, we are taking action to reduce the environmental impact of our operations.'

Novo Nordisk hopes that by supporting its suppliers to use renewable power, it will also be contributing to a reduction in emissions more broadly, as other companies may benefit from their suppliers' shift to greater sustainability.

About Novo Nordisk's 'Circular for Zero' environmental strategy

The environmental strategy challenges Novo Nordisk to find new ways to design products that can be recycled or re-used, reshape the business to minimise consumption and waste, and work with suppliers who share the company's goal.

Novo Nordisk is already taking the first steps towards zero environmental impact. But the company is always searching for new ways to do more and believes the answers will come as the business adopts a circular mindset that keeps the products and materials in use. Read more here.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries.


Charlotte Zarp-Andersson

Tel: +45 30 79 76 03

Email: czpa@novonordisk.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
10:15aNOVO NORDISK A/S : quaterly earnings release
10/26NOVO NORDISK A/S : – Share repurchase programme
10/16NOVO NORDISK : Buy rating from Goldman Sachs
10/14NOVO NORDISK : Buy rating from JP Morgan
10/12NOVO NORDISK : Credit Suisse gives a Buy rating
10/12NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..
10/12NOVO NORDISK A/S : Conference call regarding updated 2020 outlook 9 October 2020
10/12NOVO NORDISK A/S : Alexander Mann Solutions partners with Novo Nordisk to suppor..
10/12NOVO NORDISK A/S : – Share repurchase programme
10/09EUROPE : European stocks rack up second week of gains, Pandora leaps
More news
Sales 2020 128 B 20 291 M 20 291 M
Net income 2020 42 262 M 6 708 M 6 708 M
Net cash 2020 10 720 M 1 701 M 1 701 M
P/E ratio 2020 23,9x
Yield 2020 2,09%
Capitalization 1 001 B 159 B 159 B
EV / Sales 2020 7,75x
EV / Sales 2021 7,26x
Nbr of Employees 43 526
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 430,75 DKK
Spread / Highest target 26,5%
Spread / Average Target 3,92%
Spread / Lowest Target -29,2%
EPS Revisions
Lars Fruergaard JÝrgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S13.53%162 074
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381